Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $311.63 million. The enterprise value is $101.02 million.
Important Dates
The last earnings date was Friday, March 6, 2026, before market open.
| Earnings Date | Mar 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 64.65 million shares outstanding. The number of shares has increased by 46.80% in one year.
| Current Share Class | 64.65M |
| Shares Outstanding | 64.65M |
| Shares Change (YoY) | +46.80% |
| Shares Change (QoQ) | +62.82% |
| Owned by Insiders (%) | 13.76% |
| Owned by Institutions (%) | 45.00% |
| Float | 49.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.50, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.50 |
| Quick Ratio | 17.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.12% and return on invested capital (ROIC) is -27.71%.
| Return on Equity (ROE) | -43.12% |
| Return on Assets (ROA) | -26.07% |
| Return on Invested Capital (ROIC) | -27.71% |
| Return on Capital Employed (ROCE) | -26.76% |
| Weighted Average Cost of Capital (WACC) | 6.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.06M |
| Employee Count | 53 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +185.71% in the last 52 weeks. The beta is 0.45, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +185.71% |
| 50-Day Moving Average | 4.96 |
| 200-Day Moving Average | 5.32 |
| Relative Strength Index (RSI) | 42.31 |
| Average Volume (20 Days) | 838,344 |
Short Selling Information
The latest short interest is 11.07 million, so 17.12% of the outstanding shares have been sold short.
| Short Interest | 11.07M |
| Short Previous Month | 11.42M |
| Short % of Shares Out | 17.12% |
| Short % of Float | 22.41% |
| Short Ratio (days to cover) | 13.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.38M |
| Pretax Income | -56.02M |
| Net Income | -56.02M |
| EBITDA | -59.02M |
| EBIT | -59.38M |
| Earnings Per Share (EPS) | -$1.27 |
Full Income StatementBalance Sheet
The company has $172.83 million in cash and $3.82 million in debt, with a net cash position of $213.19 million or $3.30 per share.
| Cash & Cash Equivalents | 172.83M |
| Total Debt | 3.82M |
| Net Cash | 213.19M |
| Net Cash Per Share | $3.30 |
| Equity (Book Value) | 218.48M |
| Book Value Per Share | 3.38 |
| Working Capital | 166.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$45.34 million and capital expenditures -$142,226, giving a free cash flow of -$45.49 million.
| Operating Cash Flow | -45.34M |
| Capital Expenditures | -142,226 |
| Depreciation & Amortization | 353,784 |
| Net Borrowing | n/a |
| Free Cash Flow | -45.49M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.80% |
| Shareholder Yield | -46.80% |
| Earnings Yield | -17.83% |
| FCF Yield | -14.48% |
Analyst Forecast
The average price target for Immuneering is $17.20, which is 256.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.20 |
| Price Target Difference | 256.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -14.31% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
